Correlation of receptor occupancy of metabotropic glutamate receptor subtype 1 (mGluR1) in mouse brain with in vivo activity of allosteric mGluR1 antagonists

Journal of Pharmacological Sciences

Volumn 110, Issue 3, 2009, Pages 315-325

  Suzuki, Gentaroh ^a,b   Kawagoe Takaki, Hiroko ^a   Inoue, Takao ^a   Kimura, Toshifumi ^a   Hikichi, Hirohiko ^a   Murai, Takashi ^a   Satow, Akio ^a   Hata, Mikiko ^a   Maehara, Shunsuke ^a   Ito, Satoru ^a   Kawamoto, Hiroshi ^a   Ozaki, Satoshi ^a   Ohta, Hisashi ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Allosteric antagonist; Central nervous system; Metabotropic glutamate receptor; Radioligand binding; Receptor occupancy

Indexed keywords

3,5 DIHYDROXYPHENYLGLYCINE; 4 [1 (2 FLUOROPYRIDIN 3 YL) 5 METHYL 1H 1,2,3 TRIAZOL 4 YL] N ISOPROPYL N METHYL 3,6 DIHYDROPYRIDINE1(2H) CARBOXAMIDE; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR ANTAGONIST; RADIOLIGAND; UNCLASSIFIED DRUG;

ARTICLE; BEHAVIORAL SCIENCE; CHO CELL; DRUG INHIBITION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

EID: 67849111398     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09011FP     Document Type: Article

References (36)

1. Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol. 1997;37: 205-237. (Pubitemid 27238875)
2. Litschig S, Gasparini F, Rueegg D, Stoehr N, Flor PJ, Vranesic I, et al. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol Pharmacol. 1999;55:453-461. (Pubitemid 29128101)
3. Carroll FY, Stolle A, Beart PM, Voerste A, Brabet I, Mauler F, et al. BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol Pharmacol. 2001; 59:965-973. (Pubitemid 32381574)
4. Li L, Tomlinson R, Wang Y, Tsui HCT, Chamberlain MJ, Johnson MP, et al. A novel series of potent and selective noncompetitive antagonists of metabotropic glutamate receptor 1. Neuropharmacology. 2002;43:295.
5. Malherbe P, Kratochwil N, Knoflach F, Zenner MT, Kew JN, Kratzeisen C, et al. Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor. J Biol Chem. 2003;278:8340-8347. (Pubitemid 36800582)
6. 3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol Pharmacol. 2003;63:1082-1093.
7. Lavreysen H, Wouters R, Bischoff F, Nóbrega Pereira S, Langlois X, Blokland S, et al. JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist. Neuropharmacology. 2004;47:961-972. (Pubitemid 39535837)
8. Kohara A, Toya T, Tamura S, Watabiki T, Nagakura Y, Shitaka Y, et al. Radioligand binding properties and pharmacological characterization of 6-amino-N-cyclohexyl-N,3-dimethylthiazolo [3,2-a]benzimidazole-2-carboxamide (YM-298198), a highaffinity, selective, and noncompetitive antagonist of metabotropic glutamate receptor type 1. J Pharmacol Exp Ther. 2005;315:163-169.
9. El-Kouhen O, Lehto SG, Pan JB, Chang R, Baker SJ, Zhong C, et al. Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonist. Br J Pharmacol. 2006;149:761-774. (Pubitemid 44748069)
10. Varty GB, Grilli M, Forlani A, Fredduzzi S, Grzelak ME, Guthrie DH, et al. The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles. Psychopharmacology (Berl). 2005;179:207-217. (Pubitemid 40576708)
11. Kohara A, Nagakura Y, Kiso T, Toya T, Watabiki T, Tamura S, et al. Antinociceptive profile of a selective metabotropic glutamate receptor 1 antagonist YM-230888 in chronic pain rodent models. Eur J Pharmacol. 2007;571:8-16. (Pubitemid 47284045)
12. Zhu CZ, Baker S, EI-Kouhen O, Lehto SG, Hollingsworth PR, Gauvin DM, et al. Analgesic activity of metabotropic glutamate receptor 1 antagonists on spontaneous post-operative pain in rats. Eur J Pharmacol. 2008;580:314-321.
13. De Vry J, Horváth E, Schreiber R. Neuroprotective and behavioral effects of the selective metabotropic glutamate mGlu(1) receptor antagonist BAY 36-7620. Eur J Pharmacol. 2001;428:203-214.
14. Kohara A, Takahashi M, Yatsugi S, Tamura S, Shitaka Y, Hayashibe S, et al. Neuroprotective effects of the selective type 1 metabotropic glutamate receptor antagonist YM-202074 in rat stroke models. Brain Res. 2008;1191:168-179.
15. Chapman A, Nanan K, Meldrum BS, Schreiber R, De Vry J, Müller T. Anticonvulsant activity in mice of BAY 36-7620, a novel, selective mGluR1 antagonist. Soc Neurosci Abstracts. 2000;618.11.
16. Shannon HE, Peters SC, Kingston AE. Anticonvulsant effects of LY456236, a selective mGlu1 receptor antagonist. Neuropharmacology. 2005;49 Suppl 1:188-195.
17. Pietraszek M, Sukhanov I, Maciejak P, Szyndler J, Gravius A, Wislowska A, et al. Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur J Pharmacol. 2005;514:25-34. (Pubitemid 40692760)
18. Steckler T, Lavreysen H, Oliveira AM, Aerts N, Van Craenendonck H, Prickaerts J, et al. Effects of mGlu1 receptor blockade on anxiety-related behaviour in the rat lick suppression test. Psychopharmacology (Berl). 2005;179:198-206. (Pubitemid 40576707)
19. Belozertseva IV, Kos T, Popik P, Danysz W, Bespalov AY. Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur Neuropsychopharmacol. 2007;17:172-179. (Pubitemid 44779190)
20. Satow A, Maehara S, Ise S, Hikichi H, Fukushima M, Suzuki G, et al. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric mGluR1 antagonist, FTIDC, (4-[1-(2-fluoropyridine-3- yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine- 1(2H)-carboxamide). J Pharmacol Exp Ther. 2008;326:577-586.
21. Aiba A, Kano M, Chen C, Stanton ME, Fox GD, Herrup K, et al. Deficient cerebellar long-term depression and impaired motor learning in mGluR1 mutant mice. Cell. 1994;79:377-388. (Pubitemid 24324926)
22. Conquet F, Bashir ZI, Davies CH, Daniel H, Ferraguti F, Bordi F, et al. Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1. Nature. 1994;372:237-243. (Pubitemid 24352443)
23. 3H]R214127. Neuropharmacology. 2004;46:609-619.
24. Suzuki G, Kimura T, Satow A, Kaneko N, Fukuda J, Hikichi H, et al. Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5- methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H) -carboxamide (FTIDC). J Pharmacol Exp Ther. 2007;321:1144-1153.
25. Hikichi H, Iwahori Y, Murai T, Maehara S, Satow A, Ohta H. Face-washing behavior induced by the group I metabotropic glutamate receptor agonist (S)-3,5-DHPG in mice is mediated by mGlu1 receptor. Eur J Pharmacol. 2008;586:212-216.
26. 3H] L-quisqualic acid and recombinant receptors. Z Naturforsch [C]. 2002;57:348-355.
27. Barton ME, Shannon HE. Behavioral and convulsant effects of the (S) enantiomer of the group I metabotropic glutamate receptor agonist 3,5-DHPG in mice. Neuropharmacology. 2005; 48:779-787.
28. Motulsky HJ, Christopoulos A. Fitting radioligand and enzyme kinetics data. In: Fitting models to biological data using linear and nonlinear regression. A practical guide to curve fitting. San Diego: GraphPad Software Inc.; 2003. p. 187-255.
29. Mabire D, Coupa S, Adelinet C, Poncelet A, Simonnet Y, Venet M, et al. Synthesis, structure-activity relationship, and receptor pharmacology of a new series of quinoline derivatives acting as selective, noncompetitive mGlu1 antagonists. J Med Chem. 2005;48:2134-2153. (Pubitemid 40396342)
30. Johnson MP, Nisenbaum ES, Large TH, Emkey R, Baez M, Kingston AE. Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists. Biochem Soc Trans. 2004;32:881-887. (Pubitemid 39524404)
31. Besheer J, Faccidomo S, Grondin JJ, Hodge CW. Effects of mGlu1-receptor blockade on ethanol self-administration in inbred alcohol-preferring rats. Alcohol. 2008;42:13-20.
32. Steckler T, Oliveira AF, Van Dyck C, Van Craenendonck H, Mateus AM, Langlois X, et al. Metabotropic glutamate receptor 1 blockade impairs acquisition and retention in a spatial Water maze task. Behav Brain Res. 2005;164:52-60. (Pubitemid 41253732)
33. Pin JP, De Colle C, Bessis AS, Acher F. New perspectives for the development of selective metabotropic glutamate receptor ligands. Eur J Pharmacol. 1999;375:277-294. (Pubitemid 29317611)
34. 3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine). Eur J Pharmacol. 2003;473:35-40.
35. Rosenberg DR, Macmillan SN. Imaging and neurocircuitry of OCD. In: Davis KL, Charney D, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology. The fifth generation of progress. Philadelphia: Lippincott Williams and Wilkins; 2002. p. 1621-1645.
36. Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology. 2005;30:1735-1740.